Ambev SA ADR (ABEV)vsCME Group Inc (CME)
ABEV
Ambev SA ADR
$3.29
+0.30%
CONSUMER DEFENSIVE · Cap: $53.50B
CME
CME Group Inc
$281.25
-1.95%
FINANCIAL SERVICES · Cap: $101.91B
Smart Verdict
WallStSmart Research — data-driven comparison
Ambev SA ADR generates 1208% more annual revenue ($88.21B vs $6.74B). CME leads profitability with a 63.3% profit margin vs 17.7%. ABEV appears more attractively valued with a PEG of 2.31. CME earns a higher WallStSmart Score of 65/100 (C+).
ABEV
Buy57
out of 100
Grade: C
CME
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+74.4%
Fair Value
$11.91
Current Price
$3.29
$8.62 discount
Intrinsic value data unavailable for CME.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Generating 11.6B in free cash flow
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 26.5%
Keeps 63 of every $100 in revenue as profit
Strong operational efficiency at 69.8%
Large-cap with strong market position
Conservative balance sheet, low leverage
Earnings expanding 21.3% YoY
Generating 1.2B in free cash flow
Areas to Watch
Expensive relative to growth rate
2.2% earnings growth
Revenue declined 0.1%
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ABEV
The strongest argument for ABEV centers on Free Cash Flow, Market Cap, P/E Ratio. Profitability is solid with margins at 17.7% and operating margin at 26.5%.
Bull Case : CME
The strongest argument for CME centers on Profit Margin, Operating Margin, Market Cap. Profitability is solid with margins at 63.3% and operating margin at 69.8%. Revenue growth of 14.4% demonstrates continued momentum.
Bear Case : ABEV
The primary concerns for ABEV are PEG Ratio, EPS Growth, Revenue Growth.
Bear Case : CME
The primary concerns for CME are Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
ABEV profiles as a declining stock while CME is a mature play — different risk/reward profiles.
CME carries more volatility with a beta of 0.26 — expect wider price swings.
CME is growing revenue faster at 14.4% — sustainability is the question.
ABEV generates stronger free cash flow (11.6B), providing more financial flexibility.
Bottom Line
CME scores higher overall (65/100 vs 57/100), backed by strong 63.3% margins and 14.4% revenue growth. ABEV offers better value entry with a 74.4% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ambev SA ADR
CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA
Ambev SA produces, distributes and sells beer, draft beer, carbonated soft drinks (CSD), other non-alcoholic beverages, malt and food products in the Americas. The company is headquartered in So Paulo, Brazil.
CME Group Inc
FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA
CME Group Inc. (Chicago Mercantile Exchange, Chicago Board of Trade, New York Mercantile Exchange, The Commodity Exchange) is an American global markets company. It is the world's largest financial derivatives exchange, and trades in asset classes that include agricultural products, currencies, energy, interest rates, metals, stock indexes and cryptocurrencies futures.
Visit Website →Compare with Other BEVERAGES - BREWERS Stocks
Want to dig deeper into these stocks?